StockData
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP) stock

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.90+0.19 (+5.12%)

Close on Nov 16, 2026Market cap $162.23MP/E 1.1Yield 6.41%

Oramed Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Oramed Pharmaceuticals's price to sales ratio was 76.2× on Apr 30, 2026, against 50.1× a year earlier. Over the last 5 years it ranged from 19.6× to 305.7×, with a median of 59.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202676.2×+6.4
2024Apr 30, 202469.8×+35.4
2023Dec 29, 202334.4×−122.7
2022Dec 30, 2022157.1×−29.4
2021Dec 31, 2021186.5×+149.4
2020Dec 31, 202037.0×+3.9
2019Dec 31, 201933.1×+11.8
2018Dec 31, 201821.3×−28.8
2017Dec 29, 201750.1×−75.8
2016Dec 30, 2016125.9×–

More Oramed Pharmaceuticals figures

See a number that looks wrong?